<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156504">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02058992</url>
  </required_header>
  <id_info>
    <org_study_id>293-101</org_study_id>
    <secondary_id>JapicCTI-132358</secondary_id>
    <nct_id>NCT02058992</nct_id>
  </id_info>
  <brief_title>Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty</brief_title>
  <official_title>Rozerem Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of ramelteon (Rozerem)
      when used in the routine clinical setting in patients with sleep-onset difficulty associated
      with insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a drug use surveillance planned to examine the safety and efficacy of ramelteon
      tablets when used in the routine clinical setting in patients with sleep-onset difficulty
      associated with insomnia (planned sample size, 3000)

      The usual adult dosage is 8 mg of ramelteon administered orally once daily at bedtime.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Frequency of adverse drug reactions</measure>
    <time_frame>From baseline to Week 4</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The frequency of adverse drug reactions by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with the study drug are defined as adverse drug reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep status (sleep onset latency, total sleep time, number of awakenings)</measure>
    <time_frame>From baseline to 4 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in sleep status (sleep onset latency, total sleep time, number of awakenings) from the start of the investigation will be summarized and assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient's score on the Global Impression (PGI) scale</measure>
    <time_frame>From baseline to 4 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The results of the survey using the PGI questionnaire will be scored, and 7 items (sleep onset, sleep time, sleep quality, morning awakening, morning tiredness, daytime somnolence, and daytime physical condition/function) will be summarized and assessed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3339</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Ramelteon 8 mg administered orally once daily</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>Ramelteon 8 mg tablets</description>
    <arm_group_label>Ramelteon 8 mg administered orally once daily</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Insomnia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Sleep-onset difficulty associated with insomnia

        Exclusion Criteria:

          1. Patients with previous history of hypersensitivity to an ingredient of Rozerem
             Tablets

          2. Patients with severe liver dysfunction

          3. Patients taking fluvoxamine maleate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
